Recent development of small molecular specific inhibitor of protein tyrosine phosphatase 1B
- PMID: 17039461
- DOI: 10.1002/med.20079
Recent development of small molecular specific inhibitor of protein tyrosine phosphatase 1B
Abstract
Protein tyrosine phosphatases (PTPs), a large family of signaling enzymes, play essential roles in intracellular signal transduction by regulating the cellular level of tyrosine phosphorylation to control cell growth and differentiation, metabolism, cell migration, gene transcription, ion-channel activity, immune response, cell apoptosis, and bone development. Among all PTPs, protein tyrosine phosphatase 1B (PTP1B) plays a seminal role in cellular signaling and in many human diseases, including cancer, diabetes, and obesity. Therefore, small molecular inhibitors of PTP1B can be promising drug candidates. Because of the structural homologies in many families of PTPs, it is a challenging task to find inhibitors specific to each PTP. Recent studies suggested that secondary binding pockets or peripheral binding sites around the conserved active site should be exploited to design novel potent and selective PTP1B inhibitors. In this review, we discuss the structural and biological features of small molecular PTP1B-specific inhibitors, with particular emphasis on small molecular inhibitors targeting PTP1B over the other PTPs that have been synthesized in the past 4 years.
Copyright 2006 Wiley Periodicals, Inc.
Similar articles
-
Probing the molecular basis for potent and selective protein-tyrosine phosphatase 1B inhibition.J Biol Chem. 2002 Oct 25;277(43):41014-22. doi: 10.1074/jbc.M207347200. Epub 2002 Aug 21. J Biol Chem. 2002. PMID: 12193602
-
In silico structure-based design of a potent and selective small peptide inhibitor of protein tyrosine phosphatase 1B, a novel therapeutic target for obesity and type 2 diabetes mellitus: a computer modeling approach.J Biomol Struct Dyn. 2006 Feb;23(4):377-84. doi: 10.1080/07391102.2006.10531233. J Biomol Struct Dyn. 2006. PMID: 16363874
-
Steric hindrance as a basis for structure-based design of selective inhibitors of protein-tyrosine phosphatases.Biochemistry. 2001 Dec 11;40(49):14812-20. doi: 10.1021/bi011389l. Biochemistry. 2001. PMID: 11732900
-
Bidentate inhibitors of protein tyrosine phosphatases.Antioxid Redox Signal. 2014 May 10;20(14):2225-50. doi: 10.1089/ars.2013.5710. Epub 2014 Jan 8. Antioxid Redox Signal. 2014. PMID: 24206395 Review.
-
PTP1B as a drug target: recent developments in PTP1B inhibitor discovery.Drug Discov Today. 2007 May;12(9-10):373-81. doi: 10.1016/j.drudis.2007.03.011. Epub 2007 Apr 6. Drug Discov Today. 2007. PMID: 17467573 Review.
Cited by
-
Potential of Icariin Metabolites from Epimedium koreanum Nakai as Antidiabetic Therapeutic Agents.Molecules. 2017 Jun 13;22(6):986. doi: 10.3390/molecules22060986. Molecules. 2017. PMID: 28608833 Free PMC article.
-
Kinetic characterization of the inhibition of protein tyrosine phosphatase-1B by Vanadyl (VO2+) chelates.J Biol Inorg Chem. 2017 Dec;22(8):1267-1279. doi: 10.1007/s00775-017-1500-1. Epub 2017 Oct 25. J Biol Inorg Chem. 2017. PMID: 29071441 Free PMC article.
-
PTP1B: a double agent in metabolism and oncogenesis.Trends Biochem Sci. 2010 Aug;35(8):442-9. doi: 10.1016/j.tibs.2010.03.004. Epub 2010 Apr 8. Trends Biochem Sci. 2010. PMID: 20381358 Free PMC article. Review.
-
Combined neural inactivation of suppressor of cytokine signaling-3 and protein-tyrosine phosphatase-1B reveals additive, synergistic, and factor-specific roles in the regulation of body energy balance.Diabetes. 2010 Dec;59(12):3074-84. doi: 10.2337/db10-0481. Epub 2010 Sep 28. Diabetes. 2010. PMID: 20876718 Free PMC article.
-
Investigational anti-hyperglycemic agents: the future of type 2 diabetes therapy?Endocrine. 2013 Aug;44(1):47-58. doi: 10.1007/s12020-013-9884-3. Epub 2013 Jan 25. Endocrine. 2013. PMID: 23354728 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous